Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT) — Tip-HAT  

Liver Transplant; Complications Clinical Trial

Official title: Determine the Safety/Efficacy of Ticagrelor in Post-transplant Patients With Hepatic Artery Thrombosis (HAT)

Status Not yet recruiting

Clinical Trial Summary

Hepatic artery thrombosis (HAT) represents a major cause of graft loss and mortality after Pediatric liver transplantation. Ticagrelor (a new reversible inhibitor of P2Y12 receptor with faster onset of action and greater platelet inhibition) was used to treat patients with pediatric post-transplant hepatic artery thrombosis (HAT) compared to low molecular weight heparin.

Clinical Trial Description

In pediatric patients with post-transplant hepatic artery thrombosis (HAT) , low molecular weight heparin is a commonly used method. Ticagrelor, a direct-acting and reversible ADP receptor antagonist, is now the most commonly used ADP receptor antagonist in the treatment of coronary diseases. Compared to its predecessor clopidogrel, the pharmacokinetic profil of ticagrelor is more predictable, demonstrating a faster onset of action and a more consistent platelet inhibition. However, because of the excellent antithrombotic effect and increased bleeding potential, it is recommended that major bleeding, such as OPCAB or CABG surgery, be expected with a high probability, and in case of fatal surgery, the drug should be discontinued for 5 days. The present study is to evaluate the safety and efficacy of Ticagrelor in pediatirc receipt with post-operative HAT. ;

Related Conditions & MeSH terms

• Liver Transplant; Complications
• Pediatric Disease
• Thrombosis

• NCT number: NCT04946929
• Study type: Interventional
• Source: RenJi Hospital
• Contact: Hao Feng, MD. Ph.D
• Phone: +8615000901110
• Email: surgeonfeng@live.com
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: July 31, 2021
• Completion date: March 31, 2023